Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $704.0K | $36.9M | $22.5M | $19.5M | $47.4M | $2.1M | $841.0K | $1.4M |
| Cost of revenue | $961.0K | $1.1M | $1.8M | $1.7M | $2.2M | $1.7M | $1.5M | $1.3M |
| Gross profit | −$257.0K | $35.8M | $20.7M | $17.7M | $45.2M | $437.0K | −$616.0K | $180.0K |
| Gross margin | -36.5% | 96.9% | 92.1% | 91.1% | 95.4% | 20.4% | -73.2% | 12.5% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$17.2M | $10.1M | −$8.0M | −$8.2M | $9.7M | −$22.0M | −$21.1M | −$19.4M |
| EBITDA | −$16.2M | $12.8M | −$7.0M | −$7.4M | $13.0M | −$20.0M | −$20.0M | −$19.3M |
| Net income | −$20.7M | $12.6M | −$7.9M | −$8.6M | $7.6M | −$18.6M | −$23.3M | −$22.8M |
| Net margin | -2942.5% | 34.0% | -35.1% | -43.9% | 16.1% | -868.1% | -2773.4% | -1575.8% |
| EPS (diluted) | -3.33 | 1.80 | -1.15 | -1.25 | 1.00 | -2.68 | -3.34 | -3.22 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds ADOIF.
No tracked institution reports a position in ADOIF as of their last filing.
No one on the platform has traded ADOIF yet.
| $108M |
| — |
| ETTXEntasis Therapeutics Holdings Inc. | $2.19 | -0.45% | $0 | — |
| HLVXHilleVax, Inc. | $2.09 | -0.48% | $105M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$ADOIF any body home? I hear there's a weight loss pill around here somewhere.
View on StockTwits ↗$ALT $ADOIF https://insights.greyb.com/oral-pemvidutide-glp1-glucagon-dual-agonist/ Patent from Feb 10 2026... Now I'm wondering what Altimmune's next steps and timing will be regarding the launch of PH1
View on StockTwits ↗$ADOIF $ALT Good Morning https://www.adocia.com/composants/uploads/2026/04/ADOCIA-PR-2025-ANNUAL-FINANCIAL-RESULTS.pdf
View on StockTwits ↗@Kingjake26 Im in $VKTX , $ADOIF , $CABA ,$CADL Too. Plenty of stupid bears Few proactive ones ( serious people )
View on StockTwits ↗$ADOIF Adocia today with publication of financial statements 26, probably in 1hr and Stifel initiates a buy with PT $12 just 1 hr ago. Up 26%🚀 Do we hear some $ALT ernative news?
View on StockTwits ↗$ALT Interesting that $NVO's deal with Vivtex (for "up to" $2.1B) is to get better oral bioavailability from its peptides. Meanwhile, $ADOIF already has pre-clinical data of its technology with semaglutide (5x higher bioavailability compared to NVO's SNAC technology). Seems both companies have a similar approach of loosening intestinal membranes to allow a peptide to enter the blood stream.
View on StockTwits ↗$ALT Tomorrow $PIPR meeting. + $ADOIF Q4 25 https://www.adocia.com/composants/uploads/2025/12/PR-ADOCIA-Financial-calendar-2026.pdf
View on StockTwits ↗$ALT Tomorrow $ADOIF Q4 earnings update. Will it mention the recently published patent of AdOral w/ Pemvi?
View on StockTwits ↗$ALT $ADOIF Adocia Q4 2025 earnings slated for 24th Feb, i suspect ALT joint PR with Adocia for oral pemvi ph2 MASH trial announcement on 23/24th at least.
View on StockTwits ↗$ADOIF $ALT Conmection to yesterday’s 3.8 mln / 1 minCandle DP trade at alt…?
View on StockTwits ↗$ADOIF $ALT caution-AI overview but I think this ADORAL collaboration pays off soon! LFG!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.